OpenAI has announced the acquisition of Orchestra Bio, a four-year-old AI biotech software startup, as of Tuesday. While the terms of the deal remain undisclosed, reports indicate that Orchestra had raised approximately $20 million by 2025 from investors including Andreessen Horowitz, Atria, and 8VC.

About Orchestra Bio

Orchestra Bio specializes in creating AI agents that assist biotech companies in managing various aspects of drug discovery operations. This includes:

  • Tracking finances
  • Resolving scheduling issues with clinical trials